Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study

PURPOSE: Outcomes in patients with Fabry disease receiving migalastat during the phase 3 FACETS trial (NCT00925301) were evaluated by phenotype. METHODS: Data were evaluated in two subgroups of patients with migalastat-amenable GLA variants: “classic phenotype” (n = 14; males with residual periphera...

Descripción completa

Detalles Bibliográficos
Autores principales: Germain, Dominique P., Nicholls, Kathy, Giugliani, Roberto, Bichet, Daniel G., Hughes, Derralynn A., Barisoni, Laura M., Colvin, Robert B., Jennette, J. Charles, Skuban, Nina, Castelli, Jeffrey P., Benjamin, Elfrida, Barth, Jay A., Viereck, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6752321/
https://www.ncbi.nlm.nih.gov/pubmed/30723321
http://dx.doi.org/10.1038/s41436-019-0451-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6752321/
https://www.ncbi.nlm.nih.gov/pubmed/30723321
http://dx.doi.org/10.1038/s41436-019-0451-z

Ejemplares similares